<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82595">
  <stage>Registered</stage>
  <submitdate>11/02/2008</submitdate>
  <approvaldate>13/03/2008</approvaldate>
  <actrnumber>ACTRN12608000129381</actrnumber>
  <trial_identification>
    <studytitle>Cotransplantation of mesenchymal stem cells with nonmyeloablative haploidentical peripheral blood stem cells without T cells deleted for high-risk acute leukemia: to reduce the severity of graft versus host disease and relapse</studytitle>
    <scientifictitle>Cotransplantation of mesenchymal stem cells with nonmyeloablative haploidentical peripheral blood stem cells without T cells deleted for high-risk acute leukemia: to reduce the severity of graft versus host disease and relapse</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>High-risk acute leukemia patients</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>It consisted of fludarabine 30mg/m2/day (days 6 to -2), total body irradiation (60Co) 2Gy(day -1), cyclophosphamide (CTX) 40 mg/kg/day (days -4, -2), Ara-C (cytarabine) 1.5~2.0 g/m2 (days -6 to -3), and rabbit anti-human thymocyte globulin (ATG, France) 1.5~2.0 mg/kg/d (days -4 to -1). mesenchymal stem cells administrated by Intra-bone Marrow injection into iliac bones 30 min before hematopoietic stem cells infusion at day 0.</interventions>
    <comparator>It consisted of fludarabine 30mg/m2/d (days 6 to -2), total body irradiation (60Co) 2Gy(day -1), cyclophosphamide (CTX) 40 mg/kg/day (days -4, -2), Ara-C (cytarabine) 1.5~2.0 g/m2 (days -6 to -3), and rabbit anti-human thymocyte globulin (ATG, France) 1.5~2.0 mg/kg/day (days -4 to -1). hematopoietic stem cells infused without mesenchymal stem cells co-transplantation on day 0.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Transplant ralated mortality, include conditioning complication and severe infection</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of graft-versus-host disease,include acute and chronic GVHD</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Survival</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival:from treatment begining to search time point</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Leukemia relapse rates</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>High risk leukemia patients</inclusivecriteria>
    <inclusiveminage>9</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>The patients with blast cells is over 50% in bone marrow  after chemotherapy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>8/03/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>China</country>
      <state>Beijing</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Huisheng Ai</primarysponsorname>
    <primarysponsoraddress>Affiliated Hospital of Academy of Military Medicine Science
Dongdajie Road 8
Beijing</primarysponsoraddress>
    <primarysponsorcountry>China</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Affiliated Hospital of Academy of Military Medicine Science</fundingname>
      <fundingaddress>Dongdajie Road 8
Beijing</fundingaddress>
      <fundingcountry>China</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Affiliated Hospital of Academy of Military Medicine Science</sponsorname>
      <sponsoraddress>Affiliated Hospital of Academy of Military Medicine Science
Dongdajie Road 8
Beijing</sponsoraddress>
      <sponsorcountry>China</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Background:  Severe graft-versus-host disease (GVHD) and graft rejection are still major complications of haploidentical stem cell transplantation, especially for haploidentical nonmyeloablative transplantation (Haploidentical-NST). Many data have shown that bone marrowderived mesenchymal stem cells (MSCs) have some immunosuppressive capability and enhancing hematopoietic engraftment. Based on our previous researches on  the phase I clinical trial of MSCs in humans and experiment of monkeys rhesus model, we designed a new strategy that included cotransplantation of MSCs with  Haploidentical-NST, in order to improve the effectiveness of haploidentical transplantation in  high-risk acute leukemia patients.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics Committee of Affiliated Hospital of Academy of Military Medicine Science</ethicname>
      <ethicaddress />
      <ethicapprovaldate>1/01/2007</ethicapprovaldate>
      <hrec>2007-SCT</hrec>
      <ethicsubmitdate>1/06/2005</ethicsubmitdate>
      <ethiccountry>China</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Huisheng Ai</name>
      <address>Department of Hematology
Affiliated Hospital of Academy of Military Medicine Science
Dongdajie Road 8
Beijing</address>
      <phone>+86 01066947126</phone>
      <fax>+86 01066947120</fax>
      <email>aihuisheng@sohu.com</email>
      <country>China</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Kaixun Hu</name>
      <address>Department of Hematology
Affiliated Hospital of Academy of Military Medicine Science
Dongdajie Road 8
Beijing</address>
      <phone>+86 01066947129</phone>
      <fax>+86 01066947120</fax>
      <email>hukaixun@sohu.com</email>
      <country>China</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Huisheng Ai</name>
      <address>Department of Hematology
Affiliated Hospital of Academy of Military Medicine Science
Dongdajie Road 8
Beijing</address>
      <phone>+86 01066947129</phone>
      <fax>+86 01066947120</fax>
      <email>hukaixun@sohu.com</email>
      <country>China</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>